Hsp-HIV antigen fusion therapy (StressGen)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameHsp-HIV antigen fusion therapy (StressGen)

Drug Alias Nameheat shock protein-HIV antigen fusion therapy (Stressgen)stress protein-HIV antigen fusion therapy (Stressgen)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesNventa Biopharmaceuticals Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNventa Biopharmaceuticals Corp

Active IndicationsN/A

Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A